Navigation Links
Bone Drug Fails to Prevent Breast Cancer Recurrence: Study
Date:9/26/2011

By Kathleen Doheny
HealthDay Reporter

SUNDAY, Sept. 25 (HealthDay News) -- The bone drug Zometa, once considered a promising weapon to reduce the risk of breast cancer recurrence, should not be used routinely in treatment of the disease, researchers say.

In a new study of breast cancer patients, Zometa (zoledronic acid) did not increase disease-free survival overall, and it appeared to raise the risk of a serious side effect, said study co-author Dr. Robert Coleman, a professor of medical oncology at the University of Sheffield in England.

However, "for the one-third of women in the study who had gone fully through menopause at the time of study entry, there is significant benefit in terms of both disease recurrence and overall survival," Coleman added.

The results of the trial, published online Sept. 25 in the New England Journal of Medicine, were slated to be presented Sunday at the 2011 European Multidisciplinary Cancer Congress in Stockholm. Coleman also presented findings from the study at the San Antonio Breast Cancer Symposium in late 2010.

Women receiving hormone therapy for breast cancer treatment are prone to weakening and thinning of the bone, a condition known as osteoporosis, so they often receive bone-building drugs known as bisphosphonates. Some previous research had suggested these bone drugs might also help to prevent recurrence of breast cancer.

Zometa, which is delivered intravenously, is also used to relieve pain when cancer spreads to the bone.

In the study, Coleman and his colleagues randomly assigned almost 3,400 patients with early-stage breast cancer to standard therapy or to standard therapy plus Zometa.

The research team looked at overall survival and disease recurrence for an average of nearly 5 years of follow-up. They found no significant differences between the groups. According to the study, 377 patients in the group receiving the bone drug either died or had a recurrence during the five-year study, compared to 375 in the standard therapy group.

Overall, survival rates were 85.4 percent in the bone-drug group and 83.1 percent in the standard therapy group. In each group, 77 percent had disease-free survival.

But among the Zometa users, they reported 17 cases of osteonecrosis of the jaw, a severe disease that can cause the death of jawbone tissue. Another nine women were thought to have the condition. No one in the control group developed it.

While the results suggest routine use of Zometa for women with breast cancer is not advised, the researchers said Zometa might still be of some benefit for breast cancer patients who are more than five years past menopause.

Among this group were 519 women on the bone drug and 522 on standard therapy alone. At the five-year follow up, 78.2 percent of the bone drug group were alive and free of invasive recurrence, compared to 71 percent of the standard therapy group.

"The study is probably telling us that the interaction of reproductive hormones and bone is very important in driving recurrence of breast cancer," Coleman said.

The study was funded by Novartis AG, which makes the drug, and the National Cancer Research Network. Coleman has reported speaker fees from Novartis.

Dr. Otis Brawley, chief medical officer of the American Cancer Society, commented on the overall findings. "We had hoped that zoledronic acid would harden bone and reduce the rate of metastatic disease," he said. "We had also hoped this would increase survival. Neither occurred."

The increased risk of osteonecrosis is a concern, Brawley said. Even so, doctors must still pay attention to the prevention and treatment of osteoporosis in all cancer patients, he said.

More information

To learn more about breast cancer, visit the American Cancer Society.

SOURCES: Robert Coleman, M.D., professor of medical oncology, University of Sheffield, England; Otis Brawley, M.D., chief medical officer, American Cancer Society; Sept. 25, 2011, online New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Method to Detect When Patients Wake During Surgery Fails to Impress
2. Flaxseed Fails as Treatment for Hot Flashes
3. Clues to Why Rheumatoid Arthritis Drug Humira Fails Some Patients
4. Referral to high-volume hospitals for operations fails to improve outcomes statewide
5. Major Drug Review Research Fails to Disclose Funding Sources
6. Home dialysis effective for kidney patients after transplant fails
7. Once-Promising Heart Failure Drug Fails in Trial
8. Device Avoids Open-Heart Surgery When Artificial Valve Fails
9. State Senate Fails Idahoans Struggling With High Health Care Costs
10. Bone experts to present strategies for osteoporosis prevention and care in Dubai
11. New diagnostic imaging for lung cancer could prevent unnecessary surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Bone Drug Fails to Prevent Breast Cancer Recurrence: Study
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... education and high-level training standards for healthcare treatment providers who treat the full ... its Presidents Council. , The Presidents Council consists of the leading eating ...
(Date:1/23/2017)... ... 23, 2017 , ... Zachary Cattell, President of the Indiana ... industry expert at the 2017 Sector Summit hosted by Ivy Tech Community College ... Gerry Dick, will feature an employer and an association representative from five of ...
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers ... Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. ... bodybuilder in 2012 and in less than a year was able to turn professional, ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and individuals ... have been developed for use by nutrition educators and influencers within the ...
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing ... big-name retail buyers at the January ECRM Trade Show in Hilton Head, SC. , ... safety standards in all of its creations to help create a more traditional and ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Jan. 23, 2017 Research and Markets has ... Forecast to 2021" report to their offering. ... The interventional radiology products market ... 6.35 Billion in 2016, at a CAGR of 4.8%. This market ... The major factors driving the growth of this market are rising ...
(Date:1/23/2017)... , Jan. 23, 2017 7D ... 510(k) clearance from the U.S. Food and Drug ... Health Canada enabling the North American commercial launch ... system for spine surgery, the 7D Surgical System.  ... cutting-edge 3D optical technologies and machine vision algorithms ...
(Date:1/23/2017)... The American Pharmacists Association (APhA) is excited about Friday,s ... Areas Enhancement Act (H.R. 592) in the ... introduced in the 114 th session of Congress, ... and their patient care services. Sponsors of ... G.K. Butterfield (D-NC), Tom Reed ...
Breaking Medicine Technology: